Skip to main content
. 2019 Aug 19;4(4):e000536. doi: 10.1136/esmoopen-2019-000536

Figure 1.

Figure 1

Clinical and translational studies timeline. Ex vivo and in vitro experiments and radiological evaluations performed at different time points are shown. Two intervals are described: from the time of surgery to relapse (disease-free interval) and from the start of pembrolizumab therapy thereafter (pembrolizumab therapy). Time from the start of therapy: W6, 6 weeks, W18, 18 weeks, W9, 9 weeks, W18, 18 weeks, W27, 27 weeks, W36, 36 weeks, W45, 45 weeks. Adj, adjuvant; Fup, follow-up; NGS, next generation sequencing; PBMC, peripheral blood mononuclear cells.